TBPH Theravance Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TBPH

Price (delayed)

$17.03

Market cap

$884.18M

P/E Ratio

15.92

Dividend/share

N/A

EPS

$1.07

Enterprise value

$702.14M

?
Relative Growth: Rel. Growth: 71
Relative Strength: Rel. Strength: 58
Relative Valuation: Rel. Valuation: 78
Relative Profitability: Rel. Profitability: 93

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference ® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development ...

Highlights
The company's quick ratio has surged by 101% YoY and by 2.7% QoQ
TBPH's equity is up by 29% year-on-year
The gross profit has grown by 35% YoY but it has contracted by 5% from the previous quarter
TBPH's revenue is up by 35% year-on-year but it is down by 5% since the previous quarter
Theravance Biopharma's EPS has shrunk by 53% QoQ
The net income has plunged by 53% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.theravance.com
Peers: MDWD LITS

Key stats

What are the main financial stats of TBPH

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
0%
1 week
0%
1 month
0.12%
1 year
21.04%
YTD
-8.98%
QTD
0.18%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$104.31M
Gross profit
$104.31M
Operating income
-$4.2M
Net income
$53.81M
Gross margin
100%
Net margin
51.6%
Theravance Biopharma's operating margin has surged by 92% YoY
The operating income has soared by 89% YoY
The net income has plunged by 53% from the previous quarter
Theravance Biopharma's net margin has shrunk by 51% QoQ

Price vs fundamentals

How does TBPH's price correlate with its fundamentals

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
TBPH P/E details
P/E
15.92
P/B
3.03
P/S
8.44
EV/EBIT
11.69
EV/EBITDA
10.66
EV/Sales
6.73
Theravance Biopharma's EPS has shrunk by 53% QoQ
TBPH's P/E is 11% above its last 4 quarters average of 14.3
TBPH's equity is up by 29% year-on-year
The price to book (P/B) is 26% higher than the 5-year quarterly average of 2.4 but 2.3% lower than the last 4 quarters average of 3.1
TBPH's revenue is up by 35% year-on-year but it is down by 5% since the previous quarter
The P/S is 16% lower than the 5-year quarterly average of 10.0

Efficiency

How efficient is Theravance Biopharma business performance
The ROE has soared by 181% YoY but it has plunged by 56% from the previous quarter
The ROIC has plunged by 62% from the previous quarter but it has grown by 48% YoY
Theravance Biopharma's return on sales has shrunk by 54% QoQ but it has increased by 4.2% YoY
The company's return on assets has shrunk by 54% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 161% more than its total liabilities
TBPH's current ratio has surged by 102% year-on-year and by 3% since the previous quarter
The company's quick ratio has surged by 101% YoY and by 2.7% QoQ
Theravance Biopharma's debt is 87% lower than its equity
The debt to equity fell by 38% YoY and by 7% QoQ
TBPH's equity is up by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.